S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
D000109:Acetylcholine / Q000378:metabolism; D000818:Animals; D002144:Callithrix; D002478:Cells, Cultured; D004195:Disease Models, Animal; D018491:Dopamine Agonists / Q000494:pharmacology / Q000627:therapeutic use*; D018492:Dopamine Antagonists / Q000494:pharmacology; D004347:Drug Interactions; D020820:Dyskinesias / Q000188:drug therapy* / Q000209:etiology; D004594:Electrophysiology; D005110:Extracellular Space; D006801:Humans; D018476:Hypokinesia / Q000139:chemically induced / Q000188:drug therapy; D007211:Indoles / Q000627:therapeutic use*; D007980:Levodopa / Q000494:pharmacology / Q000627:therapeutic use; D020267:MPTP Poisoning / Q000188:drug therapy*; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use; D010078:Oxazines / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D017448:Receptors, Dopamine D2 / Q000819:agonists / Q000378:metabolism; D050637:Receptors, Dopamine D3; D012110:Reserpine / Q000494:pharmacology; D012399:Rotation
C493593:DRD3 protein, human; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; C493595:Drd3 protein, rat; D007211:Indoles; D018696:Neuroprotective Agents; D010078:Oxazines; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; C478818:S 32504; C046649:ropinirole; D007980:Levodopa; D012110:Reserpine; D000109:Acetylcholine